The Autonomic Nervous System and Obesity
OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE
About this trial
This is an interventional diagnostic trial for OBESITY focused on measuring OBESITY, RESTING ENERGY EXPENDITURE, SYMPATHETIC NERVOUS SYSTEM, HYPERTENSION, AUTONOMIC FAILURE
Eligibility Criteria
Inclusion Criteria: Healthy normal (BMI <= 25 Kg/m2), obese (BMI between 30 and 40)volunteers, lean hypertensive (BMI 20-28 Kg/m2), and obese hypertensive (BMI between 30 and 40) Ages 18-60 Patients with pure autonomic failure and multiple system atrophy ages 18-80, referred to our service for the diagnosis and treatment of their condition, and their age sex-matched sedentary, healthy controls ages 18-80 Exclusion criteria: All medical students Pregnant women Heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction, glaucoma History of serious allergies or asthma Subjects using beta-blockers
Sites / Locations
- Vanderbilt University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Other
Other
Other
Other
Other
Part 1
Part 2 (closed)
Part 3
Part 4a (closed)
Part 4b (closed)
Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.